• Dr. Reddy’s received a USFDA Form 483 with three observations following a pre-approval inspection and GMP inspection at its Srikakulam plant.
• The inspection at the FTO-SEZ Process Unit-02 ran from July 20, 2026, to July 29, 2026.
• The company plans to respond to the observations within the required timeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001575872-26-000538), on July 29, 2026, and is solely responsible for the information contained therein.